Cook C M, Spurrett B, Murray H
Department of Obstetrics and Gynaecology, University of Sydney at Nepean Hospital Penrith, New South Wales, Australia.
Aust N Z J Obstet Gynaecol. 1999 Nov;39(4):414-9. doi: 10.1111/j.1479-828x.1999.tb03124.x.
This is a multicentre, blocked, randomized trial to compare the efficacy of oral misoprostol 400 microg with current injectable uterotonic agents (oxytocin/ Syntometrine) used prophylactically in the third stage of labour. Main outcome measures were blood loss, use of a second uterotonic agent and difference in haemoglobin level from antepartum to postpartum. Data analysis from 863 women showed a statistically significant increase in both the mean blood loss (p < 0.001) and the rate of postpartum haemorrhage > 500 mL, (RR 2.72: 95% C1 1.73-4.27) in the misoprostol group compared to the oxytocin/Syntometrine group. The use of a second uterotonic agent was higher in the misoprostol group (RR 2.89: 95% Cl 2.00-4.18) as well as a greater decrease in postpartum haemoglobin (p = 0.015). Oral misoprostol 400 microg is significantly less effective than the traditional intramuscular uterotonic agents currently used and therefore cannot be considered as a viable option to these agents in the management of the third stage of labour.
这是一项多中心、分层、随机试验,旨在比较口服400微克米索前列醇与目前预防性用于第三产程的注射用宫缩剂(缩宫素/合成宫缩素)的疗效。主要结局指标为失血量、第二剂宫缩剂的使用情况以及产前至产后血红蛋白水平的差异。对863名女性的数据分析显示,与缩宫素/合成宫缩素组相比,米索前列醇组的平均失血量(p<0.001)和产后出血>500 mL的发生率(RR 2.72:95%CI 1.73 - 4.27)在统计学上均显著增加。米索前列醇组使用第二剂宫缩剂的比例更高(RR 2.89:95%CI 2.00 - 4.18),产后血红蛋白下降幅度也更大(p = 0.015)。口服400微克米索前列醇的效果明显低于目前使用的传统肌肉注射宫缩剂,因此在第三产程管理中不能被视为这些药物的可行替代方案。